Disease relevance of Nicainoprol

• Nicaïnoprol, a new class 1 antiarrhythmic drug was given intravenously in a dose of 2 mg kg-1 of body weight (two patients) and 3 mg kg-1 of body weight (nine patients), and the clinical, electrocardiographic and electrophysiological effects were studied [1].
• Nicainoprol could be useful in the prevention and treatment of arrhythmias associated with acute myocardial infarction [2].
• Given to anesthetized rats, nicainoprol (5 and 10 mg/kg i.v.) reduced dose dependently in the early post occlusion (0-30 min) period, the percentage of animals with premature ventricular complexes (PVCs) and ventricular tachycardia while completely preventing the occurrence of ventricular fibrillation [2].
• The effect of the novel antiarrhythmic agent nicainoprol on coronary occlusion and reperfusion arrhythmia was investigated in isolated working rat hearts and in anesthetized rats [2].
• Effects of nicainoprol on reperfusion arrhythmia in the isolated working rat heart and on ischemia and reperfusion arrhythmia and myocardial infarct size in the anesthetized rat [2].

High impact information on Nicainoprol

• Disposition kinetics and dynamics of nicainoprol, a new antiarrhythmic agent, in humans [3].
• 2. In normal sheep Purkinje fibres, lignocaine, disopyramide, nicainoprol and propranolol all significantly reduced action potential height and the maximum rate of depolarization of phase zero (MRD) and abbreviated the action potential, without modifying resting membrane potential (RMP) [4].
• Modelling frequency- and voltage-dependent effects of a class I antiarrhythmic drug (nicainoprol) on Vmax of the cardiac action potential from guinea-pig papillary muscle [5].
• At normal resting membrane potential (RMP approximately -86 mV) nicainoprol (3.3 x 10(-6) mol/l and 10(-5) mol/l) causes no Vmax-reduction after a resting period (i.e. no resting block) but a frequency-dependent decrease of Vmax (frequency-dependent block), which saturates at above 2.0 Hz [5].
• Both doses of nicainoprol induced a decrease in heart rate, blood pressure and myocardial oxygen consumption [2].

Anatomical context of Nicainoprol

• Nicainoprol induced some central nervous system effect including vomiting in conscious coronary ligated dogs [6].

Analytical, diagnostic and therapeutic context of Nicainoprol

• Nicainoprol in plasma and urine was determined by a specific HPLC assay [3].
• The results suggest that nicainoprol is an enzyme-limited or poorly extracted drug suitable for both intravenous and oral administration and devoid of beta-blocking action in humans, at least with doses tested in this study [3].
• Dose-related antiarrhythmic effects of nicainoprol in patients with chronic ventricular arrhythmias--a double-blind, placebo-controlled, cross-over multicentre trial. Nicainoprol Study Group [7].
• Determination of nicainoprol, a new antiarrhythmic agent, in human plasma and urine by high-performance liquid chromatography [8].
• Though intravenous nicainoprol (5 mg/kg) was not effective on 24 hr coronary ligation arrhythmia, an oral dose of 30 to 40 mg/kg was effective [6].

References